Latest 10-K annual reports

AbCellera Biologics Inc. reported a 161% revenue increase and reduced net loss in 2025, driven by a patent settlement and clinical pipeline advancements.

Luxfer Holdings PLC reported a decrease in net sales but an increase in adjusted net income for 2025, driven by strategic divestitures and operational improvements despite softness in some end-markets.

Vaxcyte initiated multiple Phase 3 trials for its 31-valent pneumococcal vaccine candidate, VAX-31, following positive Phase 1/2 results and expanded Breakthrough Therapy Designation, while also raising $632.5 million in a public offering.

CeriBell, Inc. announced a 36% revenue increase to $89.1 million in 2025, driven by expanded adoption of its AI-powered Ceribell System and new FDA clearances for delirium and pediatric/neonatal seizure monitoring, despite continued net losses.

Vertex, Inc. announced a significant turnaround to net income in 2025, alongside robust revenue growth and strategic investments in AI and global e-invoicing solutions, despite a slight dip in customer retention metrics.

Celanese Corporation reported a net loss of $1.151 billion for 2025, driven by lower sales volumes, pricing pressures, and significant goodwill and intangible asset impairment losses, despite deleveraging efforts.

Innovex International, Inc. announced a 48% increase in revenues for 2025, driven by strategic acquisitions and market share gains, despite a decline in net income due to prior year's non-recurring gains.

Stanley Black & Decker reports 2025 revenues of $15.1 billion, exceeding cost reduction targets while navigating portfolio divestitures and legal challenges.

New Mountain Finance Corporation reported a net decrease in net assets for 2025, driven by significant unrealized depreciation, while announcing a strategic asset sale and a quarterly dividend.

Addus HomeCare Corporation reported a significant increase in net service revenues and net income for the fiscal year ended December 31, 2025, driven by organic growth and strategic acquisitions across its personal care, hospice, and home health segments.

BlueLinx Holdings Inc. reports a significant decline in net income and gross profit for fiscal 2025 despite a slight increase in net sales, driven by strategic acquisition and volume growth offset by pricing pressures.

Northern Trust Corporation reported a 2% decrease in total revenue for 2025, driven by lower noninterest income, despite an 11% increase in net interest income and robust capital ratios.

Avanos Medical, Inc. reported a significantly reduced net loss in 2025, driven by strategic acquisitions and divestitures, despite ongoing restructuring costs and a goodwill impairment.

Old Dominion Freight Line reports a decline in 2025 revenue and net income amidst a soft domestic economy, while maintaining strong customer service and yield management.

DigitalOcean Holdings, Inc. announced a 15% revenue increase to $901.4 million in 2025, alongside a 207% surge in net income, fueled by significant growth in Digital Native Enterprise customers and AI/ML platform expansion.

Atlas Energy Solutions Inc. reported a net loss of $50.3 million in 2025, driven by declining proppant prices and increased operating costs, despite strategic acquisitions and growth in its power segment.

Offerpad Solutions Inc. reports a significant revenue decline in 2025 due to reduced home sales, but narrows its net loss through cost-cutting and strategic focus on higher-margin services, while addressing NYSE listing compliance.

Organon & Co. reported a 3% decrease in 2025 worldwide sales to $6.2 billion, a $301 million goodwill impairment, and identified material weaknesses in internal controls, while pursuing debt reduction and portfolio adjustments.

Stifel Financial Corp. achieved record net revenues of $5.53 billion in 2025, an 11.3% increase, despite a 6.9% decrease in net income available to common shareholders to $646.5 million, primarily due to significant legal provisions.

Axogen, Inc. reported a 20.2% increase in revenue for 2025, driven by product volume and pricing, alongside FDA approval for its key Avance product.

Light & Wonder achieved revenue and earnings growth in 2025, driven by strategic acquisitions and digital expansion, despite a net income decline due to significant legal settlements and restructuring costs.

Beta Bionics, a medical device company, reported significant revenue growth and increased iLet adoption in its 2025 annual filing, despite ongoing operating losses and regulatory scrutiny.

ONEOK, Inc. reports significant earnings growth in 2025 driven by strategic acquisitions and higher volumes, alongside substantial capital projects and a dividend increase.

Fidelity National Information Services (FIS) reports mixed 2025 results amidst a major strategic pivot, including the sale of its remaining Worldpay stake and a significant Issuer Solutions acquisition.

First Citizens BancShares reports a 21% decrease in net income for 2025 to $2.21 billion, alongside strategic acquisitions, increased share repurchases, and robust capital ratios.

SI-BONE, Inc. reported a 20.2% revenue increase to $200.9 million in 2025, driven by expanded product offerings and physician base, despite incurring a net loss of $18.9 million.

EXLSERVICE Holdings, Inc. announced robust financial results for fiscal year 2025, with significant revenue and net income growth fueled by its data and AI-led solutions and strategic operational shifts.

Gilead Sciences, Inc. reported a 2% increase in total revenues to $29.4 billion in 2025, driven by robust HIV product sales and significant R&D pipeline advancements, despite challenges in Veklury and Cell Therapy sales.

Alight, Inc. reported a significant $3.124 billion goodwill impairment in 2025, leading to a substantial net loss, and announced the replacement of its cash dividend with debt deleveraging and share repurchases.

CTS Corporation announced a 5.2% increase in net sales and a 17.7% rise in net earnings for 2025, driven by diversified markets and operational improvements.